Indication: Invasive Aspergillosis or Invasive Mucormycosis

A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy andPharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects

Drug Study

Principal Investigator: Victoria A Statler, M.D.
Norton Children's Infectious Diseases, affiliated with the UofL School of Medicine

Sponsor: Astellas Pharma Global Development Inc.

Search our entire site.